# Applicant

Focus Diagnostics, Inc. 11331 Valley View Street Cypress, California 90630 USA

2023365

Establishment Registration No. Contact Person

JUL 1 3 2012

Tara Viviani tel 562.240.6115 fax 562.240.6530 tviviani@focusdx.com

Summary Date Proprietary Name

May 18, 2012

Simplexa T Flu AB & RSV Direct Simplexa ™ Flu AB & RSV Positive Control Pack Respiratory Viral Panel

# Generic Name

Classification Regulation

Class II, Special Controls   
$\ S 2 1$ CFR 866.3980 - respiratory viral panel multiplex nucleic acid   
assay   
OCC  respiratory virus panel nucleic acid assay system   
Prodesse, ProFlu $^ +$ Assay (K092500, K081030, K073029)

Product Code Predicate Devices

# INTENDED USE

T Focus Dosi SplexaFlu B  RSV D assay n u   ngrat lt respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and pty nncleigils and is not intended to detect influenza C.

Neativresult oot precue nflenz vius rVnecn an should ot besed shesole bas treatment or other patient management decisions.

eestlihcl leur infenza season when 2009 H1N1infuenzaand H3N2 were the predominant nfluenza  viruses n circulation. When other influenza A viruses are emerging, performance characteristics may vary.

recommended by public health authorities, specimens should be collected with appropriate infection control v ean culture should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

# INTENDED USE

o Dasti' SmplexaFlu AB &RSV Positiv Conrol ac is ntened o be used s a conol wh e Simplexa™ Flu AB & RSV Direct kit.This control is not intended for use with other assays or systems.

# Device Description

The Simplexa™ Flu AB & RSV Direct assay system is a real-time RT-PCR system that enables the direct lintioA RNA and RSV RNA from unprocessed nasopharyngeal swabs that have not undergone nucleic acid extraction.The yse consist e Smplexau  &  rec assay, he  Integrated ycler it Inegrate ce Studio Software), the Direct Amplification Disc and associated accessories.

In the Simplexa™ Flu AB & RSV Direct assay, b-unctinal fuorescent probe-primers ae used together ih cnig ever pers pliyu ,  SV n inteal conrolAeassay provi

# 510(k) Summary Simplexa™ FIu A/B & RSV Direct - REF MOL2650 Simplexa™ Flu A/B & RSV Positive Control Pack - REF MOL2660 Prepared Date: 12.July.2012 Page 2 of 7

arenty heus heAalcn u eecand/or inhibition.

The 3M Integrated Cycler is a rapid real-time Polymerase Chain Reaction thermocycler used for the identification of nucleic acid from prepared biological samples. The instrument utilizes disk media to contain and to process samples.The instrument uses real time flourometric detection to identify argets within the sample wells.The instrument is controled by an external computer running the Integrated Cycler Studio software.

Predicate Device Information   

<table><tr><td rowspan=1 colspan=1>Trade Name / Method</td><td rowspan=1 colspan=1>510(k)submitter</td><td rowspan=1 colspan=1>.510(k)number</td><td rowspan=1 colspan=1>Decision Date</td><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>ProductCode(s)</td></tr><tr><td rowspan=1 colspan=1>ProFlu+</td><td rowspan=1 colspan=1>GenProbe(Prodesse)</td><td rowspan=1 colspan=1>K092500,K081030K07302</td><td rowspan=1 colspan=1>08/20/200905/02/200801/04/2008</td><td rowspan=1 colspan=1>Microbiology(83)</td><td rowspan=1 colspan=1>OCC</td></tr></table>

# Comparison to Predicate Device

<table><tr><td rowspan=1 colspan=1>EY</td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>*ItemName</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Simplexa™M Flu AB.&amp; RSV Direct</td><td rowspan=1 colspan=1>ProFlu+-}$</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The Focus Diagnostics Simplexa™ FluA/B &amp; RSV Direct assay is intended foruse on the 3M Integrated Cyclerinstrument for the in vitro qualitativedetection and discrimination ofinfluenza A virus, influenza B virus, andrespiratory syncytial virus (RSV) RNAin nasopharyngeal swabs (NPS) fromhuman patients with signs andsymptoms of respiratory tract infectionin conjunction with clinical andepidemiological risk factors. This test isintended for use as an aid in thedifferential diagnosis of influenza A,influenza B, and RSV viral infections inhumans and is not intended to detectinfluenza C.Negative results do not precludeinfluenza virus or RSV infection andshould not be used as the sole basis for.treatment or other patient managementdecisions.Performance characteristics for influenza Awere established with clinical specimenscollected during the 2010/2011 influenzaseason when 2009 H1N1 influenza andH3N2 were.the predominant influenza Aviruses in circulation. When other influenzaA viruses are emerging, performancecharacteristics may vary.</td><td rowspan=1 colspan=1>The ProFlu TM+ Assay is a multiplex Real-Time PCR (RT-PCR) in vitro diagnostictest for the rapid and qualitative detectionand discrimination of Influenza A Virus,Influenza B Virus, and RespiratorySyncytial Virus (RSV) nucleic acidsisolated and purified from nasopharyngeal(NP) swab specimens obtained fromsymptomatic patients. This test isintended for use to aid in the differentialdiagnosis of Influenza A, Influenza B andRSV viral infections in humans and is notintended to detect Influenza C.Negative results do not preclude influenzaor RSV virus infection and should not beused as the sole basis for treatment orother management decisions. It isrecommended that negative RSV resultsbe confirmed by culture. Performancecharacteristics for Influenza A Virus wereestablished when Influenza A/H3 andA/H1 were the predominant Influenza Aviruses in circulation. When otherInfluenza A viruses are emerging,performance characteristics may vary.If infection with a novel Influenza A virusis suspected based on current clinical andepidemiological screening criteriarecommended by public healthauthorities, specimens should becollected with appropriate infection controlprecautions for novel virulent Influenza</td></tr></table>

510(k) Summary Simplexa™ Flu A/B & RSV Direct - REF MOL2650 Simplexa™ Flu A/B & RSV Positive Control Pack - REFMOL2660 Prepared Date: 12.July.2012 Page 3 of 7   

<table><tr><td rowspan=2 colspan=1>ItemName</td><td rowspan=1 colspan=1>Devicex</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Simplexa™M Flu A/B &amp; RSV Direct</td><td rowspan=1 colspan=1>ProFlu+</td></tr><tr><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>If infection with a novel Influenza Avirus is suspected based on currentclinical and epidemiological screeningcriteria recommended by public healthauthorities, specimens should becollected with appropriate infectioncontrol precautions for novel virulentInfluenza viruses and sent to state orlocal health department for testing. Viralculture should not be attempted inthese cases unless a BSL 3+ facility isavailable to receive and culturespecimens.</td><td rowspan=1 colspan=1>viruses and sent to state or local healthdepartment for testing. Viral cultureshould not be attempted in these casesunless a BSL 3+ facility is available toreceive and culture specimens.</td></tr><tr><td rowspan=1 colspan=1>Assay Targets</td><td rowspan=1 colspan=1>Influenza A, Influenza B, RSV</td><td rowspan=1 colspan=1>Influenza A, Influenza B, RSV</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>NPS</td><td rowspan=1 colspan=1>NPS</td></tr><tr><td rowspan=1 colspan=1>ExtractionMethods</td><td rowspan=1 colspan=1>None</td><td rowspan=1 colspan=1>Roche MagNA Pure LC Total NucleicAcid Isolation Kit,Biomérieux NucliSENS easyMAG</td></tr><tr><td rowspan=1 colspan=1>AssayMethodology</td><td rowspan=1 colspan=1>PCR-based system for detecting thepresence / absence of viral RNA inclinical specimens</td><td rowspan=1 colspan=1>PCR-based system for detecting thepresence / absence of viral DNA/RNA inclinical specimens</td></tr><tr><td rowspan=1 colspan=1>DetectionTechniques</td><td rowspan=1 colspan=1>Multiplex assay using different reporterdyes for each target.</td><td rowspan=1 colspan=1>Multiplex assay using different reporterdyes for each target.</td></tr><tr><td rowspan=1 colspan=1>Influenza A ViralTarget</td><td rowspan=1 colspan=1>Well conserved region of the matrixgene</td><td rowspan=1 colspan=1>Matrix gene</td></tr><tr><td rowspan=1 colspan=1>Influenza B ViralTarget</td><td rowspan=1 colspan=1>Well conserved region of the matrixgene</td><td rowspan=1 colspan=1>Non-structural NS1 and NS2</td></tr><tr><td rowspan=1 colspan=1>RespiratorySyncytial ViralTarget</td><td rowspan=1 colspan=1>M gene.</td><td rowspan=1 colspan=1>Polymerase</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>Analytical sensitivity (LoD) as definedas the lowest concentration at which 95% of all replicates tested positive,ranges from 10^² - 10-3 TCIDso/mL.</td><td rowspan=1 colspan=1>Analytical sensitivity (LoD) as defined asthe lowest concentration at which ≥ 95%of all replicates tested positive,ranges from 10² - 101 TCIDs/mL.</td></tr><tr><td rowspan=1 colspan=1>Reproducibility</td><td rowspan=1 colspan=1>Influenza A = %CV of 0.4 to 1.5Influenza B = %CV of 0.5 to 3.6RSV = %CV of 1.2 to 3.3</td><td rowspan=1 colspan=1>Influenza A = %CV of 1.4 to 5.3Influenza B = %CV of 0.7 to 3.1RSV = %CV of 1.5 to 8.3</td></tr></table>

# PERFORMANCE CHARACTERISTICS

# CLINICAL AGREEMENT - PROSPECTIVE STUDY

Tl    il cr  fmeeu epol

# 510(k) Summary Simplexa ™ FIu A/B & RSV Direct - REFMOL2650 implexaT Flu A/B & RSV Positive Control Pack - REFMOL2660 Prepared Date: 12.July.2012 Page 4 of 7

specmens wee obtained from prospectively collected specmensfrom patients wit sis and symptoms vial ratoyracinotivpls weolasniStatve 11-March-201he Mid-WesterUnited States from08-January-2011o02-February 2011 an inAustralia frm August-2010 to 20-October-2010.Of the72 specimens 325 specimens were collected from female patients an 397 specimens were collected from male patents. A total of 327 specimens were from patients $\mathtt { < } 5$ years of age, 223 spemens were from patients between 522 year ge 8 specimens were from patients between 2 to60 yer of age and 14 specimens were from patients $\mathtt { > 6 0 }$ years of age, One (1) sample was excluded from the prospective ple c val  u e w results was $0 . 4 \%$ (3/722) with a $9 5 \%$ Cl of $0 . 1 \%$ to $1 . 2 \%$ .

Clinical Agreement - Flu A (Prospective - All sites combined)   

<table><tr><td rowspan=1 colspan=2>·*s     Culture Result</td><td rowspan=1 colspan=2>Simplexa ™ Results - Flu A</td><td rowspan=2 colspan=1>Sensitivity/Specificity         95% Cl.73.</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2      ^&quot;</td><td rowspan=1 colspan=1>yi Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>Sensitivity: 97.1%(66/68)95% CI: 89.9 to 99.2%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>653</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>639</td><td rowspan=1 colspan=1>Specificity: 97.9%(639/653)95% CI: 96.4 to 98.7%</td></tr></table>

Clinical Agreement - Flu B (Prospective - All sites combined)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa™ Results - FluB</td><td rowspan=2 colspan=1>Sensitivity/Specificity95% CI</td></tr><tr><td rowspan=1 colspan=1>t </td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Sensitivity: 100.0%(21/21)95% Cl: 84.5 to 100.0%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>698</td><td rowspan=1 colspan=1>1.</td><td rowspan=1 colspan=1>697</td><td rowspan=1 colspan=1>Specificity: 99.9%(697/698)95% Cl: 99.2 to 100.0%</td></tr></table>

Clinical Agreement  RSV (Prospective - Site 1)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa ™ Results — RSV</td><td rowspan=2 colspan=1>Sensitivity/Specificity95% Cl : :</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N i</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Sensitivity: 100.0%(1/1)* 95% CI: 20.7 to 100.0%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>329</td><td rowspan=1 colspan=1>6a</td><td rowspan=1 colspan=1>323</td><td rowspan=1 colspan=1>Specificity: 98.2%(323/329)95% Cl: 96.1 to 99.2%</td></tr></table>

4/6 samples were confirmed as RSV positive by an FDA cleared NAT

Clinical Agreement - RSV (Prospective - Site 2)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa ™ Results  RSV</td><td rowspan=2 colspan=1>Sensitivity/Specificity95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ny</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>Sensitivity: 98.6%(72/73)95% CI: 92.6 to 99.8%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>172</td><td rowspan=1 colspan=1>18b</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>Specificity: 89.5%(154/172)95% Cl: 84.1 to 93.3%</td></tr></table>

a) 1/1 sample confirmed as RSV positive by an FDA cleared DFA ) 11/18 samples confirmed as RSV positive by an FDA cleared DFA

# 510(k) Summary Simplexa™ Flu A/B & RSV Direct - REF MOL2650 Simplexa™ Flu A/B & RSV Positive Control Pack -REFMOL2660 Prepared Date: 12.July.2012 Page 5 of 7

Clinical Agreement  RSV (Prospective - Site 3)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa ™ Results  RSV.</td><td rowspan=2 colspan=1>Sensitivity/Specificity          ξ95% CI</td></tr><tr><td rowspan=1 colspan=1>.\}$  &gt;.</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Sensitivity: 90.0%(9/10)95% Cl: 59.6 to 98.2%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>21a</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>Specificity: 84.6%(115/136)95% Ci: 77.5 to 89.7%</td></tr></table>

a) 20/21 samples confirmed as RSV positive by an FDA cleared NAT

# CLINICAL AGREEMENT - RETROSPECTIVE STUDY

l anl a retrospectively banked specimens from patients with signs and symptomsf viral respiratory tract infection.

Clinical Agreement - Flu A (Retrospective - All sites combined)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa Results - Flu A</td><td rowspan=2 colspan=1>  PPA/NPA        :.95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>PPA: 96.2% (76/79)95% Cl: 89.4 to 98.7%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>.143</td><td rowspan=1 colspan=1>NPA: 99.3% (143/144)95% Cl: 96.2 to 99.9%</td></tr></table>

\* PPA $\simeq$ Positive Percent Agreement, NPA $=$ Negative Percent Agreement

Clinical Agreement - Flu B (Retrospective - All sites combined)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa ™ Results - Flu B</td><td rowspan=2 colspan=1>PPANPA*95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>PPA: 97.6% (40/41).95% Cl: 87.4 to 99.6%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1>NPA: 100.0% (182/182)95% CI: 97.9 to 100.0%</td></tr></table>

\* PPA $\asymp$ Positive Percent Agreement, NPA $=$ Negative Percent Agreement

Clinical Agreement - RSV (Retrospective - All sites combined)   

<table><tr><td rowspan=1 colspan=2>Culture Result</td><td rowspan=1 colspan=2>Simplexa ™ Results —RSV</td><td rowspan=2 colspan=1>PPAINPA*95% CI</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not Detected</td></tr><tr><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>PPA:100.0%(12/12)95% Cl: 75.7 to 100.0%</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>NPA: 98.6%(208/211)95% Cl: 95.9 to 99.5%</td></tr></table>

\* PPA $=$ Positive Percent Agreement, NPA $\simeq$ Negative Percent Agreement

# ANALYTICAL SENSITIVITY/LIMIT OF DETECTION

The Lim  Detection LoD) was eteried r he Simplexa™FuB&RV Direct assay using quantid scks i with $29 5 \%$ deection at least 9 out of 0 replicates) was determined to be the limit of detection or each assy.

# 510(k) Summary Simplexa™ Flu A/B & RSV Direct - REF MOL2650 Simplexa™ Flu A/B & RSV Positive Control Pack - REFMOL2660 Prepared Date: 12.July.2012 Page 6 of 7

Simplexa ™ Flu A/B & RSV Direct Limit of Detection   

<table><tr><td rowspan=1 colspan=1>Viral Strainsi: -       ∼·</td><td rowspan=1 colspan=1>LoD (TCID5o/mL)3           2</td></tr><tr><td rowspan=1 colspan=1>Influenza A/PR/8/34 (H1N1)</td><td rowspan=1 colspan=1>0.005</td></tr><tr><td rowspan=1 colspan=1>Influenza A/HongKong/8/68 (H3N2)</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Swine NY/02/2009 (H1N1)</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>InfluenzaB/Great Lakes/1739/54</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>InfluenzaB/Malaysia/2506/2004</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>RSV A2</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>RSV B CH93-18(18)</td><td rowspan=1 colspan=1>3</td></tr></table>

# ANALYTICAL REACTIVITY / CROSS REACTIVITY

# Analytical Reactivity

if vs ll os spiked into negative swab matrix at a single dilution with a concentration of approximately $1 . 0 \times 1 0 ^ { 2 }$ or $1 . 0 \times 1 0 ^ { 3 }$ $T C \vert \Delta _ { 5 0 } / m L$ a ssyn pliat valsi uri tg dia vil tras wee s LoD. All strains tested were appropriately detected.

# Cross Reactivity (Analytical Specificity)

Tl inan ivco la similar clinical symptoms, or present as normal flora in the specimen types of interest.

c.esi ati was o te     aSls we esd  pl l replicates, an additional 5 replicates were tested for confirmation.

No cross reactivity was detected for Flu A, Flu B or RSV

# INTERFERENCE

The peoancef ths assy was evaluatd wit poteniay ntererg subsans that may b pret n evaluated in a contrived sample that contained influenza A (influenza APR/8/34 H1N1) at a concentration o $0 . 0 1$ $T C : D _ { 5 0 } / m L$ and influenza B (influenza B/Malaysia/2506/2004) at a concentration of 40 $T C 1 0 \approx \Delta t m L$ and RSV A2 at a concentration of 4 $T C 1 D _ { 5 0 } / m L$ . All strains were tested at two to four times the LoD. There was no evidence of interference caused by the substances tested.

<table><tr><td rowspan=1 colspan=1>Potential Interferents</td><td rowspan=1 colspan=1>Active Ingredient</td><td rowspan=1 colspan=1>InterferentConcentration</td></tr><tr><td rowspan=1 colspan=1>Afrin Nasal Spray</td><td rowspan=1 colspan=1>Oxymetazoline</td><td rowspan=1 colspan=1>15% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Antibacterial, systemic</td><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>4 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Antibiotic, nasal ointment</td><td rowspan=1 colspan=1>Mupirocin</td><td rowspan=1 colspan=1>6.6 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Blood</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>2%(V/V)</td></tr><tr><td rowspan=1 colspan=1>Purified Mucin Protein</td><td rowspan=1 colspan=1>Bovine Submaxillary Gland Type I-S</td><td rowspan=1 colspan=1>60 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Nasal Corticosteroid - BeconaseAQ</td><td rowspan=1 colspan=1>Beclomethasone</td><td rowspan=1 colspan=1>5% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Nasal Corticosteroid - Fluticasone</td><td rowspan=1 colspan=1>Fluticasone</td><td rowspan=1 colspan=1>5% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Relenza Antiviral Drug</td><td rowspan=1 colspan=1>Zanamivir</td><td rowspan=1 colspan=1>3.3 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Tamiflu Antiviral Drug</td><td rowspan=1 colspan=1>Oseltamivir</td><td rowspan=1 colspan=1>1 uM</td></tr></table>

# 510(k) Summary Simplexa™ Flu A/B & RSV Direct - REF MOL2650 Simplexa™ Flu A/B & RSV Positive Control Pack - REFMOL2660 Prepared Date: 12.July.2012 Page 7 of 7

<table><tr><td rowspan=1 colspan=1>Potential Interferents</td><td rowspan=1 colspan=1>Active Ingredient</td><td rowspan=1 colspan=1>InterferentConcentration</td></tr><tr><td rowspan=1 colspan=1>Zicam Nasal Gel</td><td rowspan=1 colspan=1>Luffa Opperculata, Galphimiaglauca, histaminumhydrochloricum</td><td rowspan=1 colspan=1>5% (v/v)</td></tr></table>

# INHIBITION BY OTHER MICROORGANISMS

T vhen potentially inhibitory organisms are present.

The panelf thiy o (3 potentially hiitoy oganiss wasindividually spiked nta pol w  low conenration (apprimately2times LoD)ofinfuenza A (Influenza APR/8/34H1N1), influenzaB (Inza 0) sl al lal tested for confirmation.

No inhibitory effects were confirmed for influenza A, influenza B, or RSV at the concentrations tested

# CARRY-OVER CONTAMINATION

An inteal carry-over sudy searched r he presence contamination n negative samples.The stuy was designed by aternately placing a hih positive an a egative samplen each icThe carryover eft was evaatd by parg hesrv gativeat r eegativsample wih the eperaeno reroducibility conditions.No carry-over contamination effect was seen in the Flu A, Flu Bor RSV chals.

Focus Diagnostics, Inc. c/o Tara Viviani Regulatory Affairs Project Manager 11331 Valley View Street Cypress, California 90630

Re: K120413 '. Trade/Device Name: Simplexa"Flu A/B & RSV Direct Simplexa™"Flu A/B & RSV Positive Control Pack Regulation Number: 21 CFR 866.3980 Regulation Name: Respiratory viral panel nucleic acid assay system Regulatory Class: Class ⅡI Product Code: OCC, 001 Dated: May 18, 2012 Received: May 21, 2012

Dear Ms. Viviani:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

Page 2 - Tara Viviani

CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, Jagat

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Statement

510(k) Number (if known): k120413

Device Name: SimplexaTM Flu A/B & RSV Direct SimplexaTM Flu A/B & RSV Positive Control Pack

Indications for Use:

Simplexa™M Flu A/B & RSV Direct (REF MOL2650)

The Focus Diagnostics Simplexa™ Flu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycler instrument for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use as an aid in the differential diagnosis of influenza A, influenza B, and RSV viral infections in humans and is not intended to detect influenza C.

Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established with clinical specimens collected during the 2010/201 1 influenza season when 2009 H1N1 influenza and H3N2 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to the state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

# Simplexa™M Flu A/B & RSV Positive Control Pack (REF MOL2660)

Focus Diagnostics' SimplexaTM Flu A/B & RSV Positive Control Pack is intended to be used as a control with the Simplexa™M Flu A/B & RSV Direct kit. This control is not intended for use with other assays or systems.

Prescription Use X And/Or Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)